FK506 immunosuppression for submandibular salivary gland allotransplantation in rabbit
10.5125/jkaoms.2020.46.3.197
- Author:
Akram Abdo ALMANSOORI
1
;
Namuun KHENTII
;
Kyung Won JU
;
Bongju KIM
;
Soung Min KIM
;
Jong-Ho LEE
Author Information
1. Department of Oral and Maxillofacial Surgery, School of Dentistry, Seoul National University, Seoul, Korea,
- Publication Type:ORIGINAL ARTICLE
- From:Journal of the Korean Association of Oral and Maxillofacial Surgeons
2020;46(3):197-203
- CountryRepublic of Korea
-
Abstract:
Objectives:We compared the outcomes of two different doses of FK506 (tacrolimus) for immunosuppression in submandibular salivary gland (SMG) allotransplantation.
Materials and Methods:Three SMG allotransplantation groups were established (n=6 per group) as follows: allograft rejection control (Allo-Ctrl), low dose (0.08 mg/kg) of FK506 (FK506-L), and high dose (0.16 mg/kg) of FK506 (FK506-H). Allograft survival and rejection were assessed by clinical observation, interleukin-2 levels as determined by enzyme-linked immunosorbent assay, blood sampling for complete blood count (CBC), and histological evaluation.
Results:Body weight and anorexia were higher in the FK506-H group but without a significant difference compared with the FK506-L population. CBC revealed a non-significantly reduced number of changes in the FK506-L group. Four glands in the FK506-H group and two glands in the FK506- L group were viable and functioning post-transplantation.
Conclusion:The survival rate of allotransplanted glands was higher in conjunction with the high dose of 0.16 mg/kg of FK506, with no major difference in the side-effect profile when compared with the low dose of 0.08 mg/kg short-term outcomes.
